4th Annual MarketsandMarkets

Bioprocessing of Advanced Cellular Therapies Congress-VIRTUAL (Time Zone -GREENWHICH MEAN TIME (GMT))

29th - 30th October 2020

20+

Speakers

100+

Attendees

6+

Networking Hours

4+

Sessions

Devising the effective manufacturing and quality control methods of cell therapies

Regenerative therapies are proving its acceptance in potential of cell-based therapies for chronic disorders. Since our past three editions, our aim through this conference is to provide illustrative approach to recent developments in technologies of bioprocessing of cellular therapies, to process development and addressing qualitative and regulatory hurdles.

In the 4th edition of MarketsandMarkets Bioprocessing of Advanced Cellular Therapies Congress-VIRTUAL, we would be focusing on the manufacturing, process development, regulatory aspects of cell therapies and gene therapies. The special impact would be laid on, gene delivery based therapies, car-T cell-based immunotherapies, automated manufacturing, allogenic therapies, with the aspects of hurdles in supply chain management and regulatory affairs.

Click here to view the post show report for the 2nd Annual MarketsandMarkets Cell-Gene therapy Bioprocessing Online Conference 

 

WHAT TO EXPECT

• Stem cell transplantation for cellular aspects
• Culture technology for cell & Gene therapy applications
• Ex-vivo cell and gene therapy manufacturing
• Autologous gene therapy delivery
• Conventional Car-T cell delivery
• Allogenic Car-T cell therapy application
• Quality control in manufacturing of cell therapy
• Supply chain management for cell therapy management
• Regulatory and reimbursement issues based on GMP guidelines

  • Vice Presidents
  • Directors
  • Managers
  • Heads
  • Leaders
  • Engineers
  • Scientists
  • Professors 
  • Researchers
  • Project leaders

  • Cell Culture
  • Cell Therapy
  • Upstream Processing
  • Stem Cell therapy
  • Process Development
  • Bioprocessing
  • Downstream Processing
  • Quality Control
  • Bioengineering
  • Translational Sciences
  • Scale-up/out
  • Bioprocess development
  • Quality Control
  • Biotherapeutics
  • Cell Engineering
  • Regulatory affairs

CONFERENCE AGENDA

Registrations

08:00 - 08:50

Welcome address by MarketsandMarkets

08:50 - 08:55

Opening remarks by Chairperson

Petter Bjorquist

Petter Bjorquist, CEO, Verigraft

08:55 - 09:00

Personalised organs that will revolutionise future medicine

Petter Bjorquist

Petter Bjorquist, CEO, Verigraft

09:00 - 09:30

UPSTREAM PROCESSING OF CELL & GENE THERAPIES

Bioprocessing of cells and exosomes for regenerative medicine

Ivan Wall

Ivan Wall, Professor of Regenerative Medicine, Cell & Gene Therapy Bioprocessing, Aston University

09:25 - 09:50

Automated Cell Culture Analysis – Process Development to GMP

Roystein Bulman

Roystein Bulman, European Applications Manager, Nova Biomedical

09:50 - 10:20

Development of Combinatorial Culture Technology for cell and gene therapy applications

Marina Tarunina

Marina Tarunina, Research Director, Plasticell Limited

10:20 - 10:45

Authentic human cytokines and growth factors for ATMPs from process development through GMP

Fiona Bellot

Fiona Bellot, Protein Sales Manager, Proteintech

10:45 - 11:00

The application of light scattering to viral vector analysis; Applications for research, QC and in-line process control

Kevin Jackson

Kevin Jackson, Technical Director, Wyatt Technology, UK

11:00 - 11:15

The potential of NKG2D CAR T cells as a therapy for cancer

David Gilham

David Gilham, Vice President Research & Development, Celyad

11:15 - 11:50

Cell therapy development for solid tumors - Brought to the next Level by Image Cytometry

Martin Theiss

Martin Theiss, Senior Field Application Scientist, Nexcelom Bioscience

11:50 - 12:20

Networking break

12:20 - 12:20

DOWNSTREAM PROCESSING OF CELL & GENE THERAPIES

An innovative strategy for the production of clinical grade induced pluripotent stem cells

Victoria Robertson

Victoria Robertson, Quality Control Manager, RoslinCT, UK

12:40 - 12:55

Pragmatic drug development solutions for virtual and semi-virtual sponsors

Nick Meyers

Nick Meyers, VP Product Development, Boyd Consultants Ltd

12:55 - 13:10

Enabling Autologous CAR T manufacturing at point of care

Ohad Karneili

Ohad Karneili, Founder & CEO, Adva Biotechnology

13:10 - 13:35

Closing remarks

13:35 - 13:40

Networking break

13:40 - 14:10

End of Day 1

14:10 - 14:10

Registrations

08:15 - 08:50

Welcome address by MarketsandMarkets

08:50 - 08:55

Opening remarks by Chairperson

08:55 - 09:00

ANALYTICS AND QUALITY CONTROL FOR CELL AND GENE THERAPY PRODUCTS

Starting materials and standards for stem cell-based therapies

Elsa Abranches

Elsa Abranches, Acting Head, Division of Advanced Therapies Director, UK Stem Cell Bank

09:00 - 09:30

Engineering characterisation of DASGIP bioreactors towards the optimisation of iPSC-derived Cardiomyocyte differentiation process

Andrea Ducci

Andrea Ducci, Associate Professor, UCL Mechanical Engineering

09:25 - 09:50

Analysis of process related impurities in cell & gene therapy products by LC-MS

Ejvind Mortz

Ejvind Mortz, Chief Operating Officer, Alphalyse

09:50 - 10:20

Extending the shelf life of cell therapy products: No need to freeze

Steve Swioklo

Steve Swioklo, CSO and Co-founder, Atelerix Ltd

10:20 - 10:50

To go Viral, or to go Non-Viral, that is the question for cell modification

Stefano Baila

Stefano Baila, Director of Operations & Business Development, Anemocyte

10:50 - 11:15

Networking Break

11:15 - 11:30

Data management and data science tools for accelerating time to market

Christoph Herwig

Christoph Herwig, Bioprocess development & facility design, Werum IT Solutions

11:30 - 12:00

LOGISTICS, REGULATORY & INVESTMENT

Raw and starting material control for cell-based medicines

Christiane Niederlaender

Christiane Niederlaender, Regulatory Consultant and Director, AMBR Consulting

12:00 - 12:30

Delving deeper into AAV attributes: Enhanced characterization using multiple technologies

John Stenson

John Stenson, Product Manager, Nanomaterials, Malvern Panalytical

12:25 - 12:40

Public sector development of cell and gene therapies

Tristan Pritchard-Meaker

Tristan Pritchard-Meaker, , Leiden University Medical Centre

12:40 - 13:05

Unlocking value and investment opportunities in the cell-gene therapy industry

13:05 - 13:30

Closing remarks by Chairperson

13:30 - 13:35

End of Conference

13:35 - 13:35

CONFERENCE SPEAKERS

ADVISORS

Petter Bjorquist

Petter Bjorquist

CEO, Verigraft

SPEAKERS

Tristan Pritchard-Meaker

Tristan Pritchard-Meaker

, Leiden University Medical Centre

Kevin Jackson

Kevin Jackson

Technical Director, Wyatt Technology, UK

Steve Swioklo

Steve Swioklo

CSO and Co-founder, Atelerix Ltd

Ivan Wall

Ivan Wall

Professor of Regenerative Medicine, Cell & Gene Therapy Bioprocessing, Aston University

Christoph Herwig

Christoph Herwig

Bioprocess development & facility design, Werum IT Solutions

Fiona Bellot

Fiona Bellot

Protein Sales Manager, Proteintech Group

Roystein Bulman

Roystein Bulman

European Applications Manager, Nova Biomedical

Ohad Karneili

Ohad Karneili

Founder & CEO, Adva Biotechnology

Nick Meyers

Nick Meyers

VP Product Development, Boyd Consultants Ltd

Stefano Baila

Stefano Baila

Director of Operations & Business Development, Anemocyte

Petter Bjorquist

Petter Bjorquist

CEO, Verigraft

Elsa Abranches

Elsa Abranches

Acting Head, Division of Advanced Therapies Director, UK Stem Cell Bank

Andrea Ducci

Andrea Ducci

Associate Professor, UCL Mechanical Engineering

Damian Marshall

Damian Marshall

Director New Technology, Cell and Gene Therapy Catapult

Marina Tarunina

Marina Tarunina

Research Director, Plasticell Limited

David Gilham

David Gilham

Vice President Research & Development, Celyad

Christiane Niederlaender

Christiane Niederlaender

Regulatory Consultant and Director, AMBR Consulting

Luca Crippa

Luca Crippa

Downstream Supervisor, Molmed

SPONSORS

PARTNERS